INTRODUCTION {#s1}
============

Neuroblastoma (NB) is the most common childhood (15% of deaths in children) extracranial tumor of the autonomic nervous system that originates from neural crest-derived sympathoadrenal progenitors. The clinical behavior of NB is correlated with specific genomic abnormalities and high level amplification of the MYCN oncogene \[[@R1]\]. Treatment for patients with advanced disease is aggressive multimodal therapy (e.g. intensive chemotherapy, radiation, surgery, hematopoietic stem cell rescue and immunotherapy) even though the survival of these patients remains at 40--50%.

A reservoir of tumor cells (within a tumor) that has similar properties to normal stem cells might be responsible for therapy failure during long-term remission. This subpopulation of cells has been termed cancer stem cells (CSCs) or tumor-initiating cells (TICs). Although hematopoiesis is the most thoroughly studied stem cell system, local resident stem cells could maintain several other organs and many solid tumors, including NB, may contain a population of TICs \[[@R2], [@R3]\]. However, we know little about the phenotype of NB-TICs. To individuate TICs within a tumor, researchers normally focus on the study of functional stem cell-like characteristics such as self-renewal, tumorigenicity and drug resistance \[[@R4]\].

In a previous paper, we have shown that knockdown of Lamin A/C expression in NB cells inhibits cell differentiation and gives rise to a more aggressive and drug-resistant tumor phenotype \[[@R5]\]. Lamins, which are type V intermediate filaments, are the major components of the nuclear lamina. They are divided into A and B types based on similarities in their primary sequences and biological properties; A- and B-type lamins are expressed in differentiated tissues and ubiquitously, respectively \[[@R6], [@R7]\]. Additionally, the expression of A-type lamins is often reduced or absent in cells that are highly proliferative, including various malignancies \[[@R8], [@R9]\]. Based on our previous data and considering the different expression of Lamin A/C during development, we hypothesize that the lack of Lamin A/C could predispose cells toward a more immature phenotype. The aim of the present paper is to investigate whether Lamin A/C expression levels could influence the presence of TICs in NB.

Moreover, we seek to study the mechanism by which Lamin A/C could control tumor aggressiveness in NB. Changes in the composition of the nuclear membrane occur during the progression of several types of cancers \[[@R10], [@R11]\]. Good functionality of the nuclear membrane could play a crucial role in biological functions such as microRNA (miRNA) processing. miRNA expression is a complex process that requires an initial step of maturation in the nucleus, an intermediate phase of nuclear export, and a final processing of the pre-miRNA into the mature miRNA in the cytoplasm \[[@R12]\]. miRNAs are critical in controlling the self-renewal and differentiation of embryonic stem cells \[[@R13]\] and aberrant expression and/or functions of miRNAs are associated with tumorigenesis and the metastasis in many forms of cancer, including NB \[[@R14], [@R15]\]. The mechanisms leading to miRNA dysregulation in NB are still not fully understood. Several miRNAs, including the miR-17--92 cluster, are induced by the NB-specific transcription factor MYCN \[[@R16]--[@R18]\]. On the other hand, certain miRNAs, such as miR-101, influence MYCN transcription \[[@R19]\].

The data herein demonstrate that knockdown of Lamin A/C triggers the development of a TIC population with self-renewal features in human NB cells.

RESULTS {#s2}
=======

Abundance of LMNA in NB tumors is inversely correlated with that of MYCN gene {#s2_1}
-----------------------------------------------------------------------------

We analyzed the expression levels of the LMNA and MYCN genes in 23 NB biopsies obtained from the Department of Pediatrics and Infantile Neuropsychiatry of Sapienza University. The tumors were classified according to the International Neuroblastoma Pathology Classification (INPC) and staged as stages 1 to 4. Nine of 23 cases showed amplification of MYCN DNA. The expression levels of the two genes significantly inversely correlated (*p* = 0.01), independently of the DNA amplification of MYCN, in 21 out of the 23 cases analyzed; i.e., as LMNA increased, MYCN gene expression decreased (Fig. [1](#F1){ref-type="fig"}).

![The expression of LMNA and MYCN are inversely correlated in NB human biopsies\
qRT-PCR analysis of the LMNA (white) and MYCN (black) genes in 23 NB human biopsies. Data (means + SD \[*n* = 3\]) are reported as the deltaCt values normalized against the endogenous control. The deltaCt values are inversely correlated with the amount of the gene present in the sample. Statistical significance: *p* ≤ 0.01.](oncotarget-06-32821-g001){#F1}

We decided to study this inverse relationship between LMNA and MYCN gene in an *in vitro* experimental model of NB. We choose the SH-SY5Y and LAN-5 NB cell lines, with N-type morphology. The SH-SY5Y cells express Lamin A/C at high levels and have single copy of MYCN gene \[[@R20]\]; while LAN-5 cells show an amplification of the MYCN gene and do not express Lamin A/C \[[@R20]\]. In particular, since Lamin A/C has been demonstrated to play an epigenetic role in regulating gene expression and miRNAs can be targeted by MYCN, we hypothesized a possible reciprocal regulation between the two genes mediated by miRNAs.

We performed a miRNA expression profiling of LAN5 and SH-SY5Y cells using TaqMan Human MicroRNA Arrays. A total of 768 miRNAs, present in the array, were analyzed in each cell line. The distribution of the expressed miRNAs is shown in a Venn diagram where a total of 417 (66 specific and 351 common) and of 395 (44 specific and 351 common) miRNAs were found expressed in LAN-5 and SH-SY5Y cells, respectively (Fig. [2A](#F2){ref-type="fig"}). We found 359 and 337 miRNAs not expressed in SH-SY5Y and LAN-5 cells, respectively (293 not expressed at all in both cell lines). We identified a set of 202 out of the 351 common miRNAs differentially expressed at least 2-fold change between the two cell lines (99 in the LAN-5 and 103 in the SH-SY5Y cells); whereas 149 miRNAs were filtered out by the threshold applied. A scatter plot analysis shows the correlation between miRNA expression values (Ct) in LAN-5 and SH-SY5Y cell lines (Fig. [2B](#F2){ref-type="fig"}). Grey dots distributed along the bisector line represent miRNAs similarly expressed in the two lines (*n* = 149). While, red or green dots correspond to miRNAs with high expression in the LAN-5 (*n* = 165) and SH-SY5Y (*n* = 147), respectively.

![Functional analysis of miRNA target genes in LAN-5 and SH-SY5Y cell lines\
**A.** Venn diagram of expressed miRNAs in SH-SY5Y and LAN-5 cells. The number in parenthesis represents the total miRNAs expressed in each line. **B.** Scatter plot of the miRNA Ct values normalized against endogenous controls in SH-SY5Y and LAN-5 cells. Grey dots represent unchanged miRNAs between the two cell lines; green dots are the SH-SY5Y miRNAs; red dots represent LAN-5 miRNAs. **C.** Gene ontology by DAVID. In the histogram are reported the number of target genes belonging to the indicated functional categories. Red bar, LAN-5 cells; green bar, SH-SY5Y cells. Statistical significance: \**p* ≤ 0.05, \*\**p* ≤ 0.01, \*\*\**p* ≤ 0.001.](oncotarget-06-32821-g002){#F2}

Considering the specifically and the differentially expressed miRNAs we performed a functional analysis using the DIANA-mirPath 2.0 tool, and in particular the software TarBase which uniquely clusters those miRNAs whose targets are experimentally validated \[[@R21]\]. We filtered the clusters obtained based on their significance (FDR corrected *p* \< 0.05). As to be expected, target genes resulted grouped into functional categories associated with cancer phenotype. The most modulated miRNAs in both cell lines belong to pathways involved in the regulation of cell proliferation, apoptosis, and response to treatment: "p53 signaling pathway", "cell cycle", "pathways in cancer", "PI3K-Akt signaling pathway", "transcriptional misregulation in cancer". These pathways are consistent with the inherent phenotypic characteristics of the two cell lines and correlate to their different capacity to proliferate, to undergo apoptosis, to migrate and invade ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Since a single miRNA can inhibit several target mRNAs and multiple miRNAs can target a single mRNA in a combinatorial fashion, to identify more accurately the differences between the miRNome profiles of these two NB cell lines, we intersected the target genes derived from the two cell lines in order to identify the identical genes which were then removed from the analysis. In Table [1](#T1){ref-type="table"} are reported target genes, and relative miRNAs, identified only in SH-SY5Y or LAN-5 cells after removing the identical genes. The gene ontology performed using the DAVID tool on this subset of target genes evidenced that the most relevant enriched functional categories identified in SH-SY5Y cells were associated with cell migration, locomotion and cell proliferation (Fig. [2C](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). This indicates that SH-SY5Y cells, which express LMNA gene, have a reduced ability to migrate, to proliferate and hence to be aggressive. Whereas, the LAN-5 cells, which instead express MYCN gene, showed an enrichment in functional categories associated with regulation of differentiation and cell proliferation suggesting that these cells are less prone to differentiate and might show a stem-like phenotype with respect to SH-SY5Y cells (Fig. [2C](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). On the basis of these results, we hypothesize that the mutual expression of MYCN and LMNA genes could address NB cells to a stem-like or a differentiating phenotype, respectively.

###### Target genes and relative miRNAs specifically expressed only in SH-SY5Y or LAN-5 cells

  SH-SY5Y                                                                                                                                                                           
  --------------------------------------------------- -------- ---------- ---------- ---------- ---------- ------------- ------------- ------------- ---- ------------ ------------ ------------
  hsa04115:p53 signaling pathway                      22       1.08E-29   APAF1      CASP8      SESN1      MDM4          CDKN2A        TP73          18   miR-101-3p   miR-26b-5p   miR-21-5p
  ATM                                                 CCND3    SFN        PIDD1      DDB2       ZMAT3      miR-424-5p    miR-93-5p     miR-193a-5p                                  
  BID                                                 CCNE1    THBS1      RFWD2      EI24       GADD45A    miR-34a-5p    miR-24-3p     miR-374a-5p                                  
  CASP3                                               CCNG2    TP53I3     SERPINB5                                                                                                  
  hsa05200:Pathways in cancer                         51       5.47E-24   APPL1      CCNE1      FGF1       ITGA6         MMP2          TP53          36   miR-214-3p   let-7c       miR-222-3p
  AR                                                  CHUK     FGFR1      JUN        MMP9       BMP2       let-7d-5p     miR-21-5p     miR-25-3p                                    
  AXIN2                                               CRKL     FZD4       LAMC2      NFKBIA     ERBB2      miR-424-5p    miR-363-3p    miR-24-3p                                    
  BID                                                 DAPK1    HDAC1      MAP2K1     NRAS       IKBKB      miR-146b-3p   miR-93-5p     miR-503                                      
  PLD1                                                STAT1    VHL        RALA       TCF4       MMP1       miR-449a      miR-34a-5p    miR-26a-5p                                   
  PTK2                                                STAT5A   WNT1       RALB       TFG        PIK3R1     let-7f-5p     miR-223-3p    miR-28-5p                                    
  RB1                                                 TGFB2    RUNX1      TGFBR1     SKP2       PDGFB      miR-27a-3p    miR-29b-3p    miR-374a-5p                                  
  BIRC3                                               DVL2     HSP90AA1   MAPK1      PDGFA      MAPK9      miR-769-5p    miR-28-5p     miR-361-5p                                   
  BIRC5                                               E2F3     IGF1R                                       miR-221-3p    miR-199b-5p   miR-361-5p                                   
  hsa04110:Cell cycle                                 17       6.56E-21   ANAPC13    ATM        CCND3      CCNE1         CDC14A        GADD45A       14   miR-424-5p   miR-34a-5p   let7d-5p
  MDM2                                                ORC4     SFN        SKP2       TP53       HDAC1      miR-374a-5p   let-7c        miR-25-3p                                    
  CDC23                                               CDC25C   E2F3       E2F5       EP300                 mirR-503      mir-769-5p                                                 
  hsa04110:PI3K-Akt signaling pathway                 32       1.02E-07   PDGFA      MAP2K2     IGF1R      FGFR1         COL3A1        CASP9         26   let-7c       miR-449a     miR-100-5p
  PDGFB                                               MDM2     IKBKB      FGFR3      COL4A1     CCNE1      let-7f-5p     miR-503       miR-424-5p                                   
  PDGFC                                               MYB      INSR       GNG5       COL5A3     CDC37      miR-7-5p      miR-146b-3p   miR-181c-5p                                  
  PIK3CB                                              NRAS     IRS1       HSP90AA1   EIF4E      CHUK       miR-222-3p    let-7d-5p     miR-29b-3p                                   
  PPP2R1B                                             PAK1     MAP2K1     IFNB1      FGF1       COL1A1     miR-26a-5p    miR-34b-5p                                                 
  PRKAA1                                              RAF1                                                                                                                          
  hsa05202: Transcriptional misregulation in cancer   39       3.14E-03   TGFBR2     PDGFB      MEIS1      Il6           HIST2H3C      HIST1H3H      19   miR-34a-5p   miR-223-3p   miR-363-3p
  TP53                                                RUNX1    MYC        KLF3       HIST3H3    HIST1H3I   miR-146b-3p   miR-93-5p     miR-25-3p                                    
  ZEB1                                                SMAD1    MYCN       LMO2       HOXA9      HIST1H3J   miR-27a-3p    miR-26a-5p    miR-101-3p                                   
  SP1                                                 PAX3     MEF2C      IGF1R      HIST2H3A   HIST1H3E   miR-28-5p                                                                
  HIST1H3C                                            H3F3B    CEBPB      BIRC3      CDKN2C     BAIAP3                                                                              
  HDAC1                                               FOXO1    CCND2      ATM        HIST1H3B   H3F3A                                                                               
  HIST1H3A                                            GOLPH3   CDKN1B                                                                                                               

  LAN-5                                                                                                                                        
  -------------------------------------------------- ------- ---------- -------- -------- ------------- ------------- ------- --- ------------ -------------
  hsa04110:Cell cycle                                6       4.05E-32   BUB1B    ORC6     PKMYT1        SMAD3         SMAD2   2   miR-155-5p   miR-193b-3p
  PRKDC                                                                                                                                        
  hsa05200:Pathways in cancer                        21      1.12E-08   RAC2     RAD51    TCF7L1        NFKB2         SMAD2   5   miR-155-5p   miR-378a-5p
  CDH1                                               FN1     SUFU       RHOA     RAC2     miR-193b-3p   miR-200c-3p                            
  HSP90AB1                                           CASP9   MAX        NKX3-1   FGF7     miR-504                                              
  CTNNA1                                             JUP     SMAD3      FGF2     CDK2                                                          
  BAX                                                                                                                                          
  hsa04115:p53 signaling pathway                     2       1.35E-05   BAX      RCHY1                                        2   miR-504      miR-19a-3p
  hsa04110:PI3K-Akt signaling pathway                15      8.07E-03   EIF4E2   FGF2     FGF7          FLT1          GNB4    2                
  ITGB4                                              ITGB5   RHEB       PKN2     PRKCZ    miR-155-5p    miR-19a-3p                             
  THBS1                                              YWHAZ   NFKB1      PCK2     PDK1                                                          
  hsa05202:Transcriptional misregulation in cancer   2       4.32E-02   CD40     BCL2L1                                       2   miR-486-5p   miR-491-5p

###### Gene Ontology analysis on the target genes specifically expressed only in SH-SY5Y or LAN-5

  SH-SY5Y                                                                                                       
  -------------------------------------------------- ---------- -------- --------- --------- --------- -------- -------
  GO:0051726∼regulation of cell cycle                4.84E-16   25       STAT5A    SFN       CCNG2     CDC37    TGFB2
  CASP3                                              CDKN2A     CDKN2C   INSR      MYC                          
  BMP2                                               TP53       SKP2     CDC23     BIRC5                        
  RB1                                                CDC25C     ATM      CDKN1B    HDAC1                        
  CCND3                                              CCND2      JUN      MDM2      GADD45A                      
  GO:0030335∼positive regulation of cell migration   1.21E-11   13       IL6       PLD1      PDGFB     MAP2K1   PDGFA
  MMP9                                               IRS1       TGFB2    IGF1R     MAPK1                        
  THBS1                                              INSR       PIK3R1                                          
  GO:0007049∼cell cycle                              5.21E-11   29       E2F3      CDC14A    ANAPC13   SESN1    CCNG2
  TGFB2                                              CCNE1      CDKN2A   CDKN2C    THBS1                        
  MYC,                                               MAP2K1     TP53     SKP2      CDC23                        
  BIRC5                                              RB1,       CDC25C   APPL1     ATM                          
  TP73                                               MAPK1      CDKN1B   EP300     CCND3                        
  CCND2                                              MDM2       MDM4     GADD45A                                
  GO:0001952∼regulation of cell-matrix adhesion      0.002      4        CDKN2A    PIK3CB    THBS1     PIK3R1   
  GO:0007626∼locomotory behavior                     0.003      9        MAPK1     PLD1      IL6       MAP2K1   PDGFB
  PDGFA                                              PIK3CB     RALA     TGFB2                                  

  LAN-5                                                                                                      
  --------------------------------------------------------- ----------- --- ------- -------- ------- ------- -------
  GO:0051094∼positive regulation of developmental process   9.707E-05   7   BAX     RHOA     SMAD3   NFKB1   SMAD2
  THBS1                                                     FGF2                                             
  GO:0001952∼regulation of cell-matrix adhesion             0.002       3   PRKCZ   SMAD3    THBS1           
  GO:0008285∼negative regulation of cell proliferation      0.003       6   BAX     NKX3-1   SMAD3   SMAD2   THBS1
  FGF2                                                                                                       
  GO:0045597∼positive regulation of cell differentiation    0.004       5   RHOA    SMAD3    NFKB1   SMAD2   FGF2

To validate the results obtained in cell cultures we analyzed the expression of some selected miRNAs in tumor tissue RNA specimens previously studied for LMNA and MYCN expression. Among the most differentially expressed miRNAs between SH-SY5Y and LAN-5 cell lines, we chose miR-101, miR-34a, miR-424, miR-21, miR-504 and miR-92a which clearly represent the phenotypic differences between the two cell lines as concerns tumorigenicity and NB tumor progression, regulation of cell cycle, differentiation and targeting of MYCN. The distribution of the deltaCt values of all the miRNAs studied in 15 tumor tissue specimens resulted very heterogeneous as evidenced in the box plot shown (Fig. [3A](#F3){ref-type="fig"}). To obtain a more accurate analysis we divided the samples in two groups with high (≤ −1.00) and low (\> −1.00) LMNA expression (threshold = LMNA deltaCt median value), including only those specimens whose difference between LMNA and MYCN expression was at least 4-fold (12 out of 15 tumor tissue specimens). Consistent with the changes observed in the two cell lines we found an increased expression of miR-101, miR-34a, miR-424, miR-21, and a decreased expression of miR-504 and miR-92a in the NB patient group with high LMNA expression compared with the specimen group with low LMNA expression (Fig. [3B](#F3){ref-type="fig"}).

![miRNA validation in NB human biopsies\
**A.** Boxplot diagrams of deltaCt values of the indicated miRNAs. Each box represents the distribution of the deltaCt measured for a single miRNA in 15 tumor tissue specimens. Bottoms and tops of the boxes define the 25^th^ and 75^th^ percentile, the band inside the box defines the median, and the ends of the whiskers define the lowest and the highest value of all data. **B.** Data are expressed as percentage variation (+SD) of the indicated miRNAs in the NB patient group with high LMNA expression compared with the specimen group with low LMNA expression, defining high and low LMNA expression on the LMNA deltaCt median values (threshold = −1.00) (*p* = 0.008).](oncotarget-06-32821-g003){#F3}

LMNA gene knock-down induces a stem-like phenotype in SH-SY5Y cells {#s2_2}
-------------------------------------------------------------------

We used as experimental model the SH-SY5Y cells in which we previously inhibited differentiation by LMNA knock-down (LMNA-KD) \[[@R5]\]. First, we analyzed the expression of some stemness-related markers such as NANOG, SOX2, POU5f, PROM-1, CD34 and ABCG2, by qPCR (Fig. [4A](#F4){ref-type="fig"}). All of these genes were overexpressed in LMNA-KD cells, indicating that lack of the LMNA gene could be associated with a more immature cell phenotype. The activity of ABCG2, which is a member of the ATP-binding cassette (ABC) membrane transporters, and present in many types of stem cells, was also verified evaluating by FACS analysis the exclusion of the fluorescent supravital dye Hoechst 33342 out of the cells. The cells able to pump outside the dye are concentrated in a tailing population exhibiting dim fluorescence relative to the majority of cells with bright fluorescence and they represent the so called "side population", known to correlate with a stem-like phenotype. Indeed, LMNA-KD cells show the presence of a side population identified by a Hoechst 33342 low-staining fraction (approximately 5%; Fig. [4B](#F4){ref-type="fig"}). As control to confirm dye efflux and the probable presence of stem-like cells we inhibited the ABCG2 pump by verapamil. Consistently, verapamil treatment led to depletion of this side population in LMNA-KD cells. By contrast, control cells presented the same cytofluorimetric profile in both the presence and absence of verapamil.

![SH-SY5Y LMNA-KD cells acquire stemness characteristics\
**A.** qRT-PCR analysis of the indicated genes in control (CTR; white) and LMNA-KD (black) cells. The data are reported as the level of mRNA relative to the number of control cells and are the means+SD (*n* = 5). Statistical significance: \**p* ≤ 0.05, \*\**p* ≤ 0.01. **B.** Flow cytometric analysis of side population after staining with Hoechst 33342 in the absence or presence of verapamil to inhibit the functionality of the membrane ABCG2 efflux pump. **C.** Tumor sphere assay of LMNA-KD cells compared to control and LAN-5 cells; phase contrast micrographs of the secondary spheres, magnification 200X. **D.** Mean diameter (+SD) of the secondary spheres formed in LMNA-KD cells and compared with those obtained in LAN-5 cells (*p* = 0.18). The SH-SY5Y cells did not produce any measurable spheres but only aggregates. **E.** Representative confocal images of the secondary tumor spheres. CD133 immunostaining (red) and nuclear staining (blue). Scale bar: 50 μm.](oncotarget-06-32821-g004){#F4}

We then investigated the ability to form spheres by LMNA-KD cells in the appropriate culture conditions. As a positive control, we used human NB LAN-5 cells, known to form spheres \[[@R3]\]. Similarly to LAN-5 cells, LMNA-KD cells formed secondary spheres in serum-free medium (Fig. [4C](#F4){ref-type="fig"}). Noteworthy, the mean diameter of the spheres measured in LMNA-KD cells was superimposable to that of the LAN-5 positive control cells (*p* = 0.18; Fig. [4D](#F4){ref-type="fig"}). By contrast, control cells did not show any significant capacity to form secondary spheres. We carried out immunofluorescence experiments on the spheres to detect the expression of known stemness markers, such as CD133, SSEA4 and SOX2. LMNA-KD secondary spheres were positive for all the markers considered (Fig. [4E](#F4){ref-type="fig"} and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}).

LMNA-KD sphere-derived adherent cells maintain stemness characteristics and acquire a more aggressive phenotype {#s2_3}
---------------------------------------------------------------------------------------------------------------

Spheres formed from LMNA-KD cells were cultured in adherent conditions for several passages. Sphere-derived adherent cells grew as discrete groups of differently sized cells whereas the LMNA-KD cell monolayer showed a dispersed pattern, with growing cells being mainly isolated ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). We verified the expression of MYCN mRNA levels which significantly increased in LMNA-KD cells and in sphere-derived adherent cells (approximately 2-fold) compared with CTR cells thus confirming our hypothesis (Fig. [5A](#F5){ref-type="fig"}, left panel). The increased MYCN expression was associated with the down-regulation of the NDRG1 and NDRG2 genes in LMNA-KD cells and in sphere-derived adherent cells (Fig. [5A](#F5){ref-type="fig"}, right panel). An increase in the N-Myc protein accompanied the increase in MYCN gene expression in LMNA-KD cells and sphere-derived adherent cells, as evaluated by FACS analysis (approximately 40 and 65%, respectively; Fig. [5B](#F5){ref-type="fig"}).

![LMNA--KD sphere-derived adherent cells possess self-renewal and tumor progression characteristics\
**A.** RT-qPCR analysis of MYCN mRNA levels (right panel) and of NDRG1 and NDRG2 mRNA levels (left panel) in CTR cells (white), LMNA-KD cells (grey) and LMNA--KD sphere-derived adherent cells (black). The data are reported as the level of mRNA relative to CTR cells and are the means+SD (*n* = 5). Statistical significance: \**p* ≤ 0.05 \*\**p* ≤ 0.01, \*\*\**p* ≤ 0.001. **B.** FACS analysis of N-Myc expression in control and LMNA-KD cells. LAN-5 cells were used as a positive control. The number reported in each histogram represents the percent positivity. **C.** RT-qPCR analysis of the indicated genes in CTR cells (white), LMNA-KD cells (grey) and the sphere-derived adherent cell line (black). The data are reported as the level of mRNA relative to LMNA-KD cells and are the means+SD (*n* = 5). Statistical significance: \**p* ≤ 0.05, \*\**p* ≤ 0.01, \*\*\**p* ≤ 0.001. **D.** Representative immunofluorescence for Oct4 (red fluorescence) on mES culture, 4 days after exposure to growth medium lacking LIF interleukin, attesting the pluripotency of the cells. The absence of a signal for Oct4 and the presence of Lamin A/C (green fluorescence) demonstrate the luck of pluripotency and the beginning of the differentiation process. Nuclei were stained with DAPI (blue fluorescence). Scale bars: 20 μm. **E.** Relative expression of tumor aggressiveness-related genes in CTR cells (white), LMNA-KD cells (grey) and the sphere-derived adherent cell line (black). The data are reported as the level of mRNA relative to LMNA-KD cells and are the means+SD (*n* = 5). Statistical significance: \*\**p* ≤ 0.01, \*\*\**p* ≤ 0.001.](oncotarget-06-32821-g005){#F5}

We characterized the LMNA--KD sphere-derived adherent cells to evaluate the mRNA expression levels of self-renewal genes compared to those in the control cell line. The stemness marker genes maintained their expression or were further up-regulated in LMNA-KD sphere-derived adherent cells (Fig. [5C](#F5){ref-type="fig"}). In particular, we observed a strong up-regulation of the stemness network of the transcription factor genes NANOG, POU5f and SOX2 and of the drug resistance-related gene ABCG2. In addition, sphere-derived adherent cells maintained their self-renewal ability, as they were still able to form cell spheres in non-adherent culture conditions.

We used murine embryonic stem cells (mES) to study the expression of Lamin A/C protein in a pluripotent stem cell model. mES, cultured in stemness conditions, homogeneously showed the presence of OCT4 (data not shown). When Leukemia inhibitory factor (LIF, an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation) was removed from the culture medium, allowing a generic differentiation, we detected the presence of Lamin A/C in those cells that did not express OCT4 anymore, suggesting that Lamin A/C could be an exclusive characteristic of the cells that begin the differentiation process (Fig. [5D](#F5){ref-type="fig"}).

Sphere-derived adherent cells appeared to acquire a more aggressive phenotype than LMNA-KD cells (Fig. [5E](#F5){ref-type="fig"}). The ENPP2 metastasis-associated gene showed a 4-fold increase with respect to LMNA-KD cells. In addition, the EDN1 and CD44 genes, known to be involved in cell adhesion functions, significantly decreased in the sphere-derived adherent cell line.

Mainly, these data strongly suggest that LMNA--KD sphere-derived adherent cells possess self-renewal and tumor progression characteristics that are peculiar of a putative population of tumor-initiating cells (TIC-like cells).

The LMNA-KD sphere-derived adherent cell line is able to initiate tumors *in vivo* {#s2_4}
----------------------------------------------------------------------------------

We performed a limiting dilution assay in LMNA-KD sphere-derived adherent cells (namely TIC-like cells in this paper) to determine the minimum cell dilution capable of forming colonies *in vitro*. While TIC-like cells maintained colony forming ability at very low dilution (down to 16 cells), LMNA-KD cells did not form colonies at such dilution (Fig. [6A](#F6){ref-type="fig"}).

![The LMNA-KD sphere-derived adherent cell line is able to initiate tumor growth *in vivo*\
**A.** *In vitro* plating efficiency (PE %) in LMNA-KD (white) and sphere-derived adherent (black) cells at different cell dilutions. **B.** LMNA-KD (•) or sphere-derived adherent (○) cells were injected subcutaneously into the flanks of immunosuppressed mice at 10^5^ (left panel) or 5 × 10^4^ (right panel) cells/mouse in 200 μl of Matrigel. When a tumor mass was evident, the tumor sizes were measured, and the tumor weight was calculated using the following formula: *a* × b^2^/2, where a and b are the long and short diameters of the tumor, respectively. The mean ± SD tumor weights are reported (*p* = 0.003, at day 14 and *p* = 0.01 at day 21 and 28 after tumor cell injection). **C.** Histopathological examination of tumor biopsies from LMNA-KD cells and TICs after 27 days of tumor growth. Images shown are at 20X (left panels) and 40X (right panels) magnification.](oncotarget-06-32821-g006){#F6}

On this basis, we compared the *in vivo* growth of the two cell lines using an *in vivo* limiting dilution assay. Immunosuppressed mice were injected subcutaneously with different number of LMNA-KD and TIC-like cells (from 5 × 10^4^ to 1 × 10^7^). No differences in terms of tumor appearance and tumor growth were evident injecting from 2.5 × 10^5^ to 1 × 10^7^ TIC-like and LMNA-KD cells (data not shown). While, at lower number, TIC-like cells exhibited a higher growth rate than LMNA-KD cells (Fig. [6B](#F6){ref-type="fig"}); this was evident when mice were injected with 10^5^ cells (left panel), but a more marked difference between TIC-like and LMNA-KD cells was found in terms of tumor mass when 5 × 10^4^ cells were injected per mouse (right panel). In fact, a significant increase in the weight of the TIC-like-derived tumors compared to the LMNA-KD-derived tumors (an almost doubling) was observed as the maximum effect (on day 14 after tumor cell injection) (*p* = 0.003). A significant difference between the two tumor growth rate was maintained also at day 21 and 28 after tumor cell injection (*p* = 0.01).

The histopathological pattern of these tumors, analyzed on day 27 of tumor growth, showed small cells with round to oval shapes, deeply stained nuclei and poorly defined cytoplasmic outlines. Unlike LMNA-KD-derived tumors, TIC-derived tumors were mainly microscopically characterized by a nodular pattern of growth. Small aggregates with mostly hyperchromatic nuclei were defined by the presence of fibrous septa. We also observed hypercellularity and overlapping nuclei occasionally exhibiting small nucleoli in TIC-derived tumors. These findings further demonstrate the more malignant phenotype of TIC tumors (Fig. [6C](#F6){ref-type="fig"}).

MYCN expression is increased by miR-101 inhibitor in SH-SY5Y NB cells {#s2_5}
---------------------------------------------------------------------

From a more accurate analysis of the table [1](#T1){ref-type="table"} we found that MYCN gene appeared as one of the miRNA target in the SH-SY5Y cells, whereas LMNA did not emerge as a miRNA-regulated gene in the LAN-5 cells, thus indicating that the absence of MYCN expression in SH-SY5Y cell line might be the results of miRNA regulation. Since miR-101 is a specific miRNA known to target also MYCN gene \[[@R19], [@R22]\], we inhibited miR-101 in SH-SY5Y control cells to modulate MYCN expression. As control, we overexpressed miR-101 in LMNA-KD cells in order to verify the effect on MYCN gene expression. As expected, the analysis of the intrinsic expression of miR-101 in both cell lines, revealed miR-101 less expressed in LMNA-KD cells by 50% compared to SH-SY5Y control cells (Fig. [7A](#F7){ref-type="fig"}).

![Modulation of hsa-miR-101 modifies the expression of MYCN gene and in turn of stemness and cancer-related genes\
**A.** TaqMan MicroRNA Assay with hsa-miR-101 in CTR cells (white) and LMNA-KD cells (black). The data are reported as the level of mature miRNA and mRNA relative to CTR cells and are the means+SD (*n* = 5). Statistical significance: \**p* ≤ 0.05, \*\**p* ≤ 0.01. **B.** TaqMan MicroRNA Assay, with the hsa-miR-101 levels in CTR cells transfected with the inhibitor (white, left panel) or in LMNA-KD cells transfected with the mimic (black, right panel). The data are reported as the level of mature miRNA compared to each relative negative control and are the means+SD (*n* = 5). Statistical significance: \*\*\**p* ≤ 0.001. **C.** qRT-PCR analysis of the indicated genes in hsa-miR-101 mimic-transfected LMNA-KD cells (black) and hsa-miR-101 inhibitor-transfected CTR cells (white). The data are reported as the level of mRNA compared to each relative negative control and are the means+SD (*n* = 5). Statistical significance: \**p* ≤ 0.05, \*\**p* ≤ 0.01, \*\*\**p* ≤ 0.001.](oncotarget-06-32821-g007){#F7}

Transfection of SH-SY5Y control cells with the miR-101 inhibitor decreased the expression levels of miR-101 by approximately 50% (Fig. [7B](#F7){ref-type="fig"}, left panel). Transfection of LMNA-KD cells with the miR-101 mimic resulted in approximately 90-fold increased expression of miR-101 (Fig. [7B](#F7){ref-type="fig"}, right panel). The analysis of the MYCN transcripts resulted significantly increased or decreased after transduction of miR-101 inhibitor or mimic, respectively (Fig. [7C](#F7){ref-type="fig"}). We then analyzed the mRNA levels of genes involved in some of the MYCN-regulated pathways such as stemness and aggressiveness. The expression of the same genes up-regulated in SH-SY5Y control cells after the inhibition of miR-101, decreased in LMNA-KD cells after the overexpression of miR-101. Consistently, after inhibiting miR-101, SH-SY5Y control cells showed down-regulation of the tumor suppressor EDN1 and CD44 genes, and increased expression of the tumor progression ENPP2 gene with respect to LMNA-KD cells transfected with the miR-101 mimic (Fig. [7C](#F7){ref-type="fig"}). We also verified the effect of the N-Myc transcription factor on the LMNA gene expression by analyzing the expression of LMNA gene in SH-SY5Y in which we overexpressed MYCN either by inhibiting miR-101 or by ectopically transducing a MYCN construct. In both cases we did not observe any increase in the expression of the LMNA gene and of the Lamin A/C protein (data not shown).

DISCUSSION {#s3}
==========

This paper demonstrates that the down regulation of Lamin A/C expression in the SH-SY5Y NB cells allows the development of a tumor-initiating cell (TIC) population with self-renewal features and the ability to initiate tumors *in vivo*.

TICs have been identified in many tumor types as a small tumorigenic population of cells that are responsible for sustaining tumor growth and metastatic spread, thus representing the cause of cancer recurrence \[[@R23]--[@R25]\]. Their presence has been demonstrated in the bone marrow of patients with relapsed NB \[[@R2]\], and they have many stem cell characteristics, such as sphere-forming ability and self-renewal. However, sphere-forming ability is not a general characteristic of NB tumor-derived cell lines, as reported by Mahller and colleagues \[[@R3]\], who studied the capacity to give rise to spheres in eight NB cell lines, including SH-SY5Y. In accordance with these authors, we also found that NB SH-SY5Y cells were not able to form spheres. However, when we silenced the LMNA gene in these cells, they gave rise to spheres in serum-free culture conditions that were optimized for neural stem cell growth. The capacity to form spheres clearly demonstrates that this selected population possesses the self-renewal characteristics of a stem cell phenotype. Pluripotency is a unique state in which cells can self-renew indefinitely while maintaining the ability to differentiate. The mechanism that controls the transcription of core pluripotency factors has been extensively studied \[[@R26], [@R27]\]. In normal embryonic stem cells, the gene regulatory networks of the core transcription factors Oct4, Nanog and Sox2 are involved in pluripotency maintenance \[[@R27]\]. Consistently, we found that the three main genes belonging to the stem cell regulatory network (POU5f, which encodes Oct4, NANOG and SOX2) were all significantly overexpressed in LMNA-KD-derived tumor spheres and even more so when the sphere cell population was cultured as adherent cells.

In addition, the fact that these spheres are highly positive for the CD133, SOX2 and SSEA4 markers further supports the stem-like phenotype of LMNA-KD cells.

We also found in LMNA-KD-derived tumor spheres a marked increase in the expression of the ABC membrane transporter gene ABCG2. Increased expression of this gene is considered a major characteristic of the cancer stem cell population that is associated with different tumor types \[[@R28]\]. The increased expression of this drug resistance-related gene often correlates with the presence of a side population \[[@R29]\]. Indeed, we found the unambiguous presence of a side population completely abolished by the exposure to verapamil, a known inhibitor of the membrane drug efflux-pump, in LMNA-KD cells.

To further corroborate that this cell population with self-renewal characteristics was a TIC population, we studied the capacity of these cells to give rise to tumors. The analysis of tumor growth *in vivo* clearly demonstrated that the putative TICs were more markedly aggressive, as evidenced by their significant higher growth rate at low cell concentrations than the LMNA-KD whole cell population and by the more malignant phenotype of the tumor tissues. It is likely that the enhanced tumorigenicity of TICs may depend on their maintenance in supportive micro-environmental "niches". In normal tissues a "niche" consists of a microenvironment formed by cellular and non-cellular components which together are able of housing and maintaining stem cell homeostasis. On the other hand, there is evidence that the normal cells that surround and infiltrate tumors secrete factors that promote the growth and progression of cancer. Vermeulen et al. \[[@R30]\] reported that the microenvironment was imperative for regulating functional activity associated to colon TICs. Similarly, Calabrese et al. \[[@R31]\] demonstrated that brain vascular niche is responsible for promoting self-renewal and accelerating tumor growth from brain TICs. As reported by others in different tumor types including neuroblastoma \[[@R2], [@R32]\] we also used Matrigel in our *in vivo* studies in order to provide to TICs a complete microenvironment and biological substrates to promote TIC xenograft tumor formation.

The aggressiveness of the TIC population was also evidenced by increase of ENPP2 and decrease of EDN1 and CD44 gene expression. We can therefore conclude that the LMNA-KD sphere-derived cells represent a TIC population.

The inverse relationship between LMNA and the NB marker MYCN found in the TICs indicate that these two genes could mutually regulate differentiation and stemness in NB. Indeed, TICs which express more MYCN than SH-SY5Y control cells and are silenced for LMNA gene, also show a significant increase of the NANOG, POU5f and SOX2 gene expression. This is supported by the data obtained from biopsies of human NB. Indeed, we found, for the first time in this paper, a defined inverse relationship between LMNA and MYCN gene expression in 23 human NB biopsies.

On the other hand, the miRNome analysis in two NB cellular model expressing LMNA or MYCN alternatively, evidenced changes of members of miRNA signatures which control cell proliferation and differentiation. In fact, in the SH-SY5Y LMNA expressing cells DAVID pathway analysis revealed that the miRNA target genes belonged mainly to pathways related to cell cycle regulation indicating that the expression of Lamin A/C is associated with a more mature phenotype. This confirm data of a previous paper from our laboratory where we demonstrated that LMNA knock-down inhibit differentiation processes. By the contrary, in the LAN-5 MYCN expressing cells the miRNA target genes identified belonged to pathways related to the inhibition of the developmental processes. In particular, some of these genes (SMAD2/3, FGF2) appear to be involved in stem cell differentiation processes \[[@R33], [@R34]\]. The very different number of miRNAs identified in each cluster comparing the two cell lines support our hypothesis. It is likely that miRNAs and their target genes in LAN-5 cells tend to display a low number of clusters as a consequence of reduced number of pathways to be regulated to maintain their stem-like phenotype. By contrast, SH-SY5Y cells need to control a higher number of pathways than LAN-5 cells, due to their more mature phenotype. On the other hand, it is important to highlight that the analysis has been performed considering uniquely validated target. The validation in NB human specimens of some of the relevant miRNAs differentially expressed in the two NB cell lines confirms in the tumor biopsies the expression profiles obtained in the two cell lines. This suggests that this group of miRNAs could be the basis for a further identification of a miRNA signature representative of tumor progression in relation to LMNA expression.

The MYCN crucial role in the control of tumor initiating cell development is further demonstrated by data obtained modulating MYCN expression through miR-mediated regulation. The choice to modulate MYCN by miR-101 mediated regulation is based on the analysis of the miRNA array performed in SH-SY5Y and LAN-5 cells (see [supplementary table 1](#SD1){ref-type="supplementary-material"}). We evidenced hsa-miR-101--3p and hsa-miR-34a-5p as specific miRNAs targeting MYCN gene \[[@R19]\]. To confirm that these miRNAs were expressed at higher levels in SH-SY5Y than in LAN-5 cells we performed a qRT-PCR which confirmed the array result (data not shown). In addition, only miR-101 expression was decreased in LMNA-KD compared to control cells; while the expression of miR-34a did not change (data not shown). This suggests that only the former miRNA could have a role in regulating MYCN mRNA after LMNA knock-down. In fact, up-regulating MYCN in SH-SY5Y control cells, they acquired a stem-like phenotype; while down-regulating MYCN in LMNA-KD cells, we were able to restore a more mature phenotype. On the other hand, overexpression of the MYCN gene correlates with increased stemness characteristics \[[@R35]--[@R37]\]. In addition, the role of the MYCN gene in promoting tumor invasion, particularly in NB cells, is well known \[[@R38]--[@R40]\]. However, LMNA gene expression did not change when we increased MYCN in SH-SY5Y cells, indicating that an inverse correlation between LMNA and MYCN does not exist. Moreover, an *in silico* analysis of the LMNA promoter did not evidenced the presence of the Myc family transcription factors peculiar consensus sequence.

Our data provide new mechanistic insight into the development of a stem-like NB TIC population. In a tumor-mass, TICs constitute a rare tumorigenic cell population responsible for sustaining tumor growth, metastases and relapse. Our data may provide opportunities to develop new personalized therapeutic strategies based on the molecular profile of the tumor.

MATERIALS AND METHODS {#s4}
=====================

Human NB biopsy RNA extraction and real-time RT-PCR {#s4_1}
---------------------------------------------------

Total RNA was extracted from twenty-three frozen biopsies of human newly diagnosed NBs obtained from Department of Pediatrics and Infantile Neuropsychiatry of Sapienza University, Rome using TRIzol reagent (Life Technologies) according to the manufacturer\'s instructions. RNA was reverse-transcribed, and real-time PCR performed as described below. The amplification efficiencies of the primers for MYCN and LMNA genes were tested and resulted identical (LMNA efficiency = 2.1; MYCN efficiency = 2.0). Institutional written informed consent was obtained from the patient\'s parents or legal guardians according to the local institutional guidelines.

Cell line maintenance and sphere formation {#s4_2}
------------------------------------------

The SH-SY5Y NB cell line was purchased from ATCC. In this study, we also used two SH-SY5Y-derived clones, LMNA-KD and control (CTR) cells that were grown as previously described \[[@R5]\]. The LAN-5 NB cell line (a gift from Dr. Doriana Fruci) was grown in RPMI-1640 medium (Gibco) supplemented with 10% FBS (Hyclone), 2 mML-glutamine and 1% penicillin/streptomycin in a fully humidified incubator containing 5% CO~2~ at 37°C. To obtain spheres, cells were plated in a serum-free media in 60-mm, low-attachment culture dishes at a density of 9.5 × 10^5^ cells/cm^2^ and cultured in Neurobasal Medium (Gibco) supplemented with 20 ng/ml Epidermal Growth Factor (EGF, Sigma), 40 ng/ml basic Fibroblast Growth Factor (bFGF, Sigma), 1% neuronal supplement N2 (Gibco) and B27 (Gibco), and 2 μg/ml heparin. Three days after seeding, the cells formed floating neurosphere-like structures that grew rapidly until day 7. Before these structures became necrotic, we harvested and suspended them in Accutase enzymatic solution (Gibco) for 5 min at 37°C and then mechanically dissociated into a single-cell suspension. The cells were re-seeded in the same conditions as above, and the secondary spheres were allowed to form. As positive and negative controls, we used NB LAN-5 and SH-SY5Y cell lines, respectively. The secondary spheres were measured using ImageJ software and the value of diameter expressed in μm. TICs were derived by harvesting the secondary spheres, treating them with Accutase enzymatic solution (Gibco) for 5 min at 37°C and then mechanically dissociating them into a single-cell suspension. These cells were seeded in adherent conditions in the presence of 1:1 mixture of Eagle\'s Minimum Essential Medium and F12 medium (Gibco) supplemented with 10% FBS (Hyclone), 2 mM L-glutamine, 0.5% non-essential amino acids, 0.5% sodium pyruvate and 1% penicillin and streptomycin. mES cells were cultured following the protocol provided by ATCC (ES-D3, CRL-1934 ATCC).

Total RNA preparation {#s4_3}
---------------------

Total RNA was isolated using a Total RNA purification kit (Norgen Biotek). RNA quantity was determined by measuring absorbance at 260 nm using a NanoDrop UV-VIS spectrophotometer. The quality and integrity of each sample was confirmed using a BioAnalyzer 2100 (Agilent RNA 6000 Nanokit); samples with an RNA Integrity Number (RIN) index lower than 8.0 were discarded.

PCR array {#s4_4}
---------

RNA was reverse transcribed using TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). cDNA was preamplified using TaqMan PreAmp Master Mix (Applied Biosystems). qRT-PCR was performed with an Applied Biosystem 7900HT thermal cycler using TaqMan human microRNA array (TaqMan Human microRNA Array A \#4398977 and B v3.0 \#442812; Applied Biosystems) according to manufacturer\'s instructions. The downstream analysis filtered out miRNAs not detected in both cell lines (293), whereas those specifically expressed either in LAN-5 or in SH-SY5Y were considered and reported as cell line-specific. Data were then normalized calculating the ΔCt value for single miRNA against the average of the specific controls for each card according to manufacturer\'s instructions. Differential expression analysis was performed according to ΔΔCt method and only RQ ≥ 2 fold-change were considered for further analysis. miRNAs clusters were generated through the DIANA web tool mirPath v2.0 using miRBase MIMAT IDs (Release 21) remapped to the newest human genome assembly (GRCh38) to avoid duplicate entries present in the previous release. Uniquely targets reported in TarBase database v7.0 were included in the clustering, predicted targets were not taken into account. False Discovery Rate (FDR) correction was applied to the original *p*-value and only clusters with corrected *p*-values \< 0.05 were shown.

Real-time RT-PCR analysis {#s4_5}
-------------------------

RNA was reverse-transcribed and real time PCR analysis were performed as previously described \[[@R41]\]. The specific primers used (each at a concentration of 200 nM) are reported in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. Each experiment was performed in triplicate. The expression data were normalized using the Ct values of GAPDH and TBP.

Side population {#s4_6}
---------------

To analyze the side population phenotype, LMNA-KD cells were stained according to the protocol of Goodell et al. \[[@R42]\]. Briefly, 5.0 × 10^6^ cells/ml were suspended in pre-warmed DMEM. Hoechst 33342 (Sigma) was added at a final concentration of 5 μg/ml in the presence or absence of 50 μM verapamil (Sigma), and the cell samples were incubated for 90 min at 37°C with intermittent shaking. After incubation, the cells were washed with ice-cold PBS, resuspended in ice-cold PBS, and analyzed for Hoechst 33342 efflux with a FACS Aria II (Becton Dickinson). The Hoechst 33342 dye was excited at 375 nm, which is near-ultraviolet, and the resultant fluorescence was measured at two wavelengths, using 450/40 BP and 670 LP filters for the detection of Hoechst blue and red, respectively. All data were analyzed using the Diva 6.1 Software (Becton Dickinson).

Tumor sphere CD133 immunofluorescence {#s4_7}
-------------------------------------

Spheres were cultured as previously described, harvested and then allowed to spontaneously settle in a 50-mL polypropylene conical tube. Excess supernatant was removed. Spheres were dispensed in an 8-well μ-Slide (Ibidi) and allowed to settle, and Matrigel from a 5X Matrigel BME Coating Solution (Trevigen) was added to 0.1X. The cells were fixed in ice-cold methanol for 20 min and permeabilized in 0.5% Triton X-100 containing 0.3% serum for 10 min. Blocking was carried out in Tris-buffered saline (TBS) solution with serum (1:5) for 10 min. The primary antibody anti-CD133 (clone 293C3; Miltenyi Biotec) was diluted in the blocking solution with 0.5% Tween-20, and the spheres were incubated overnight. The cells were washed three times in TBS and incubated with goat anti-mouse Alexa 594 F(ab)2 (in TBS plus 0.5% Tween-20). After three washes in TBS, the nuclei were stained with Hoechst 33342 Images were acquired using a confocal laser scanning microscope (Leica Confocal Microsystem TCS SP5). The images were processed using Leica Application Suite 6000, the brightness and contrast of the acquired images were adjusted, and the figures were generated using Adobe Photoshop 7.0.

Immunocytochemistry in murine ES {#s4_8}
--------------------------------

mES were fixed in 4% paraformaldehyde for 10 minutes and incubated overnight at 4°C with the following primary antibodies used at 1:100: mouse monoclonal anti-Oct4 (OCT4; BD) and goat anti-Lamin A/C (JOL2; Chemicon Int.). After three washes with PBS, the cells were incubated with a 1:100 dilution of fluorescent-conjugated secondary antibodies for 1 h at room temperature. Secondary antibodies were: donkey anti-mouse IgG Alexa-Fluor 555 (Jackson ImmunoResearch) and donkey anti-goat IgG Alexa-Fluor 488 (Jackson ImmunoResearch). Negative controls were tested by incubation of only the secondary antibody without a primary antibody incubation: all secondary antibodies were negative for non-specific staining. After three washes, the sections were mounted with VECTASHIELD (Vector Laboratories) plus DAPI.

N-Myc FACS analysis {#s4_9}
-------------------

SH-SY5Y CTR, LMNA-KD cells and TICs were analyzed by indirect immunofluorescence. The cells were harvested, washed in cold 1X PBS and fixed (1 × 10^6^ cells/ml) in a solution containing cold acetone/methanol (1:4 v/v) in 50% 1X PBS. For each sample, 1 × 10^6^ cells were incubated with the human monoclonal antibody anti-N-Myc (Santa Cruz) in medium containing 10% FBS and 0.5% Tween 20 for 1 h at room temperature. After washing in PBS, the cells were incubated with FITC-conjugated goat anti-mouse IgG (BD, Pharmingen) in PBS for 50 min. After an additional wash in PBS, the samples were measured using a FACSCalibur cytofluorimeter (Becton Dickinson). Samples incubated with IgG isotype control antibody were used as negative controls, and NB LAN-5 cells were used as a positive control. The analysis was performed using the CellQuest software package. To determine the N-Myc immunofluorescence positivity we used the method of 2% of background.

Colony-forming assay {#s4_10}
--------------------

The LMNA-KD and sphere-derived adherent cell line were seeded at decreasing clonal densities (range: 15--1,000 cells/dish) in 60-mm Petri dishes. Fifteen days after seeding, the cells were fixed for 10 min in ice-cold methanol. A solution of 0.5% crystal violet in 25% methanol was added to the monolayer for 30 min. The dishes were then washed with ddH~2~O, and the colonies (at least 50 cells) were counted. The results were expressed as plating efficiency (percentage of colonies formed from the number cells seeded).

*In vivo* experiments {#s4_11}
---------------------

Six- to eight-week-old CD-1 male nude (nu/nu) mice weighing 22--24 g were purchased from Charles River Laboratories (Calco, Italy). The procedures involving mouse care were in compliance with the Regina Elena National Cancer Institute animal care guidelines and with international directives (directive 2010/63/EU of the European parliament and council; Guide for the Care and Use of Laboratory Animals, United States National Research Council, 2011). To evaluate the tumorigenic ability of LMNA-KD cells or sphere-derived adherent cells, the mice were injected subcutaneously into the left flank with various concentrations of cells (from 5 × 10^4^ to 1 × 10^7^ cells/mouse) in 200 μl of Matrigel (BD Biosciences-Discovery Labware). Each group included five mice. Tumor sizes were measured three times a week in two dimensions using a caliper, and tumor weight was calculated using the following formula: *a* × b^2^/2, where a and b are the long and short diameters of the tumor, respectively.

Histopathological analysis {#s4_12}
--------------------------

The engrafted tumors were fixed with 4% phosphate-buffered formalin, and paraffin-embedded sections were stained using hematoxylin and eosin (H&E). The sections were then subjected to morphological analysis.

miRNA assays {#s4_13}
------------

Equal amounts of RNA were reverse transcribed with the TaqMan^®^ MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer\'s instructions, with a custom 1X RT primer pool (hsa-miR-101--3p ID 002253; U6 snRNA ID 001973; hsa-miR-424 ID 000604; hsa-miR-34a ID 000426; hsa-miR-21 ID 000397; hsa-miR-504 ID 002084; hsa-miR-92a ID 000431). Real time PCR analysis was performed with an Applied Biosystems 7900HT thermal cycler using 20X Individual TaqMan^®^ MicroRNA Assays.

Hsa-miR-101 inhibitor and mimic {#s4_14}
-------------------------------

SH-SY5Y control and LMNA-KD cells were seeded at a density of 5 × 10^4^ cells/cm^2^. After 24 h, the cells were transfected overnight in the presence of 10% FBS with mirVana miRNA inhibitor, miRNA mimic or the respective negative controls. Lipofectamine RNAiMAX Reagent (Life Technologies) was used as the transfection reagent, according to the manufacturer\'s instructions. We transfected the has-miR-101 inhibitor (MH11414, Ambion) and the mimic (MC11414, Ambion) at a final concentration of approximately 50 nM. The mirVana miRNA inhibitor and mimic negative control were used at the same final concentration of 50 nM. Samples were harvested at 72 h to perform mRNA expression analysis.

Statistical analysis {#s4_15}
--------------------

Student\'s *t* test (unpaired, two-tailed) was used for statistical comparison of different tumor weights and between two groups. If there were more than two groups, we used the one-way ANOVA test.

SUPPLEMENTARY FIGURES AND TABLES {#s5}
================================
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